OncoMatch/Clinical Trials/NCT07241767
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Is NCT07241767 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin and FH-006 ; SHR-1316 ; BP102 for lung cancer.
Treatment: FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin · FH-006 ; SHR-1316 ; BP102 — Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-tumor treatment
Receive other anti-tumor treatments within 4 weeks before the first medication
Cannot have received: chest radiation therapy
Chest radiation therapy patients who received>30 Gy within 24 weeks prior to the first use of the investigational drug
Lab requirements
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07241767 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-tumor treatment, chest radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify